uric acid has been researched along with Metabolic Diseases in 214 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout." | 9.16 | Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012) |
| "This study examined the relationship between serum levels of uric acid and insulin resistance and metabolic syndrome in nondiabetic patients with schizophrenia." | 7.83 | Relationship between serum uric acid level and cardiometabolic risks in nondiabetic patients with schizophrenia. ( Cimpeanu, C; Fan, X; Harrington, A; Rajan, S; Song, X; Zalpuri, I, 2016) |
| "To identify the risk factors of kidney injuries in hypertensive patients with uric acid (UA) metabolic disorders in order to choose the optimal management tactics, by analyzing the changes in markers for endothelial dysfunction (endothelin-1 (ET-1), microalbuminuria (MAU), intima-media thickness (IMT)) and tubulointerstitial tissue lesion (beta2-microglobulin (beta2-MG, monocyte chemotactic protein-1 (MCP-1))." | 7.80 | [Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorder ( Balkarov, IM; Kozlovskaia, LV; Shcherbak, AV; Stakhova, TIu; Taranova, MV, 2014) |
| "To compare the characteristics of female versus male gout patients and assess urate-lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout." | 5.16 | Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. ( Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA, 2012) |
| " The link between increased fructose consumption and increases in uric acid also has been confirmed as a potential risk factor for metabolic syndrome, and insulin resistance/hyperinsulinemia may be causally related to the development of hypertension." | 4.91 | Health implications of high-fructose intake and current research. ( de Lima, WG; Dornas, WC; Pedrosa, ML; Silva, ME, 2015) |
| "The serum samples from hyperuricemia subjects were used to analyze the correlation between serum uric acid and clinical characteristics." | 4.31 | Pseudohypoadrenalism, a subclinical cortisol metabolism disorder in hyperuricemia. ( Bao, R; Chen, B; Chen, Q; Pan, J; Wang, A; Wang, T; Yu, H; Zhang, Y, 2023) |
| " Our study indicates that stone-forming children who are overweight or obese have low urinary volume and elevated uric acid compared to normal-weight stone-forming children." | 3.85 | Do Overweight and Obese Pediatric Stone Formers Have Differences in Metabolic Abnormalities Compared With Normal-weight Stone Formers? ( Bayne, AP; Cambareri, GM; Chiang, G; Corbett, S; Giel, DW; Kovacevic, L; Schurtz, E; Sukhu, T; Yap, M, 2017) |
| "This study examined the relationship between serum levels of uric acid and insulin resistance and metabolic syndrome in nondiabetic patients with schizophrenia." | 3.83 | Relationship between serum uric acid level and cardiometabolic risks in nondiabetic patients with schizophrenia. ( Cimpeanu, C; Fan, X; Harrington, A; Rajan, S; Song, X; Zalpuri, I, 2016) |
| "To identify the risk factors of kidney injuries in hypertensive patients with uric acid (UA) metabolic disorders in order to choose the optimal management tactics, by analyzing the changes in markers for endothelial dysfunction (endothelin-1 (ET-1), microalbuminuria (MAU), intima-media thickness (IMT)) and tubulointerstitial tissue lesion (beta2-microglobulin (beta2-MG, monocyte chemotactic protein-1 (MCP-1))." | 3.80 | [Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorder ( Balkarov, IM; Kozlovskaia, LV; Shcherbak, AV; Stakhova, TIu; Taranova, MV, 2014) |
| "Overweight, obesity, higher blood pressure, unfavorable blood lipid profile, and especially higher uric acid levels are connected with greater TAC of blood serum across an adult man's life." | 3.78 | Physical activity and total antioxidant capacity across an adult lifespan of men. ( Chrzczanowicz, J; Drygas, W; Gawron-Skarbek, A; Jegier, A; Kostka, J; Kostka, T; Nowak, D, 2012) |
| " In our study, calcium and uric acid abnormalities were the most common, and vesicoureteral reflux seemed to be the most common urological abnormality which led to urinary stasis and calculus formation." | 3.76 | Metabolic factors associated with urinary calculi in children. ( Alamdaran, SA; Naseri, M; Varasteh, AR, 2010) |
| " Each measurement was used as a main predictor in the logistic model where the presence of a metabolic risk factor (high blood pressure, high triglyceride, low high-density lipoprotein cholesterol, high glucose, and high uric acid) was predicted." | 3.75 | Use of waist circumference and ultrasonographic assessment of abdominal fat distribution in predicting metabolic risk factors in healthy Japanese adults. ( Abe, M; Hori, Y; Kimata, A; Kondo, T; Ueyama, J; Yamamoto, K, 2009) |
| "Behavioural and biological correlates of serum uric acid were investigated in 2487 men who received a retirement health examination at the Self-Defence Forces Fukuoka Hospital from October 1986 through 1990, excluding those under medication for hyperuricaemia, hypertension or hyperlipidaemia." | 3.69 | Behavioural and biological correlates of serum uric acid: a study of self-defence officials in Japan. ( Honjo, S; Imanishi, K; Kono, S; Shinchi, K; Todoroki, I, 1994) |
| "It's reported that oral administration of fructose in normal and gouty patients causes a rise in serum uric acid (see "References": Stirpe et al." | 3.67 | [Evaluation of hyperuricemia caused by fructose in a status of altered uric acid metabolism]. ( Della Corte, E; Menghini, S, 1987) |
| "The prevalence of gout and the frequency distribution of serum uric acid (SUA) concentrations have been studied in four South African populations." | 3.65 | Rheumatic disorders in the South African Negro. Part IV. Gout and hyperuricaemia. ( Beighton, P; Solomon, L; Soskolne, CL; Sweet, MB, 1977) |
| " Such a synthesis was measured in 20 healthy controls, 24 patients with primary gout (11 on allopurinol therapy) and 26 patients with chronic renal failure and secondary hyperuricemia (8 on allopurinol therapy)." | 3.65 | [De novo purine biosynthesis. In vitro measurement in hyperuricemia (author's transl)]. ( Brami, M; Brunois, JP; Chanard, J; Funck-Brentano, JL; Kamoun, P; Pleau, JM, 1977) |
| "The etiology of hyperuricemia following myocardial infarction was investigated by uric acid kinetic studies carried out on seven male patients following myocardial infarction and on two control subjects." | 3.65 | Uric acid kinetic studies in the immediate post-myocardial-infarction period. ( Crawhall, JC; Dosman, JA; Klassen, GA, 1975) |
| "In patients with hereditary fructose intolerance, fructose consumption is associated with acute hypoglycemia, renal tubular acidosis, and hyperuricemia." | 2.87 | Are heterozygous carriers for hereditary fructose intolerance predisposed to metabolic disturbances when exposed to fructose? ( Barbey, F; Bonafé, L; Braissant, O; Damjanovic, K; De Bandt, JP; Debray, FG; Mittaz-Crettol, L; Paquot, N; Rosset, R; Roux, C; Tappy, L; Tran, C, 2018) |
| "Obesity was prevalent in both groups." | 2.67 | [Forestier disease and metabolism disorders. A prospective controlled study of 25 cases]. ( Gerster, JC; Troillet, N, 1993) |
| "Comparative analysis with obesity, type 2 diabetes, ankylosing spondylitis and rheumatoid arthritis indicated that gout metagenomes were more similar to those of autoimmune than metabolic diseases." | 1.62 | Metagenomic analysis revealed the potential role of gut microbiome in gout. ( Bai, X; Chen, X; Chu, Y; Ding, F; Fang, X; Gao, Q; He, X; Huang, Q; Huang, R; Huang, Y; Jiang, Y; Li, J; Liang, L; Sun, S; Wang, M; Wang, P; Wang, Z; Wei, X; Wu, J; Wu, X; Xie, X; Yang, J; Yue, Z; Zhang, Y; Zhao, Y; Zhou, C, 2021) |
| "Uric acid was observed as a predictor of increased effort HR." | 1.46 | Relationship between Cardiometabolic Parameters and Elevated Resting and Effort Heart Rate in Schoolchildren. ( Burgos, LT; Burgos, MS; Horta, JA; Mello, ED; Reuter, CP; Sehn, AP; Silva, CFD; Silva, PTD; Welser, L, 2017) |
| "The incidence of pediatric nephrolithiasis is increasing and therefore the etiologies contributing to today's pediatric stone formation may also be changing." | 1.46 | The Modern Metabolic Stone Evaluation in Children. ( Bevill, M; Cooper, CS; Kattula, A; Storm, DW, 2017) |
| "Urolithiasis is one of the commonest problems in pediatric nephrology." | 1.36 | Clinical manifestations and etiology of renal stones in children less than 14 years age. ( Heidari, A; Sepahi, MA; Shajari, A, 2010) |
| "Although increased susceptibility to infection has been observed in subjects with diabetes or obesity, little is known about the relationship between metabolic disorders and increased susceptibility to infection." | 1.36 | Association between capacity of interferon-alpha production and metabolic parameters. ( Fukui, M; Hasegawa, G; Nakamura, N; Nakumura, N; Tominaga, M; Uno, K; Yagi, K; Yoshikawa, T, 2010) |
| "Uric acid was studied before and after administration of pyrazinamide and benzbromarone." | 1.26 | Isolated defect in postsecretory reabsorption of uric acid. ( Levinson, DJ; Sorensen, LB, 1980) |
| "The incidence of recurrence was 23." | 1.25 | [Recurrent Urolithiasis during Childhood (author's transl)]. ( Vendl, L, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 146 (68.22) | 18.7374 |
| 1990's | 13 (6.07) | 18.2507 |
| 2000's | 16 (7.48) | 29.6817 |
| 2010's | 28 (13.08) | 24.3611 |
| 2020's | 11 (5.14) | 2.80 |
| Authors | Studies |
|---|---|
| Inanc, IH | 1 |
| Sabanoglu, C | 1 |
| Li, D | 1 |
| Xiong, Q | 1 |
| Liu, W | 1 |
| Liang, L | 2 |
| Duan, H | 1 |
| Wang, J | 1 |
| Chen, Y | 1 |
| Chen, S | 1 |
| Wang, X | 1 |
| Zhai, H | 1 |
| Xu, C | 1 |
| Bao, R | 1 |
| Chen, B | 1 |
| Pan, J | 1 |
| Wang, A | 1 |
| Yu, H | 1 |
| Chen, Q | 1 |
| Zhang, Y | 2 |
| Wang, T | 1 |
| Tin, A | 1 |
| Marten, J | 1 |
| Halperin Kuhns, VL | 1 |
| Li, Y | 1 |
| Wuttke, M | 1 |
| Kirsten, H | 1 |
| Sieber, KB | 1 |
| Qiu, C | 1 |
| Gorski, M | 1 |
| Yu, Z | 1 |
| Giri, A | 1 |
| Sveinbjornsson, G | 1 |
| Li, M | 1 |
| Chu, AY | 1 |
| Hoppmann, A | 1 |
| O'Connor, LJ | 1 |
| Prins, B | 1 |
| Nutile, T | 1 |
| Noce, D | 1 |
| Akiyama, M | 1 |
| Cocca, M | 1 |
| Ghasemi, S | 1 |
| van der Most, PJ | 1 |
| Horn, K | 1 |
| Xu, Y | 1 |
| Fuchsberger, C | 1 |
| Sedaghat, S | 1 |
| Afaq, S | 1 |
| Amin, N | 1 |
| Ärnlöv, J | 1 |
| Bakker, SJL | 1 |
| Bansal, N | 1 |
| Baptista, D | 1 |
| Bergmann, S | 1 |
| Biggs, ML | 1 |
| Biino, G | 1 |
| Boerwinkle, E | 1 |
| Bottinger, EP | 1 |
| Boutin, TS | 1 |
| Brumat, M | 1 |
| Burkhardt, R | 1 |
| Campana, E | 1 |
| Campbell, A | 1 |
| Campbell, H | 1 |
| Carroll, RJ | 1 |
| Catamo, E | 1 |
| Chambers, JC | 1 |
| Ciullo, M | 1 |
| Concas, MP | 1 |
| Coresh, J | 1 |
| Corre, T | 1 |
| Cusi, D | 1 |
| Felicita, SC | 1 |
| de Borst, MH | 1 |
| De Grandi, A | 1 |
| de Mutsert, R | 1 |
| de Vries, APJ | 1 |
| Delgado, G | 1 |
| Demirkan, A | 1 |
| Devuyst, O | 1 |
| Dittrich, K | 1 |
| Eckardt, KU | 1 |
| Ehret, G | 1 |
| Endlich, K | 1 |
| Evans, MK | 1 |
| Gansevoort, RT | 1 |
| Gasparini, P | 1 |
| Giedraitis, V | 1 |
| Gieger, C | 1 |
| Girotto, G | 1 |
| Gögele, M | 1 |
| Gordon, SD | 1 |
| Gudbjartsson, DF | 1 |
| Gudnason, V | 1 |
| Haller, T | 1 |
| Hamet, P | 1 |
| Harris, TB | 1 |
| Hayward, C | 1 |
| Hicks, AA | 1 |
| Hofer, E | 1 |
| Holm, H | 1 |
| Huang, W | 1 |
| Hutri-Kähönen, N | 1 |
| Hwang, SJ | 1 |
| Ikram, MA | 1 |
| Lewis, RM | 1 |
| Ingelsson, E | 1 |
| Jakobsdottir, J | 1 |
| Jonsdottir, I | 1 |
| Jonsson, H | 1 |
| Joshi, PK | 1 |
| Josyula, NS | 1 |
| Jung, B | 1 |
| Kähönen, M | 1 |
| Kamatani, Y | 1 |
| Kanai, M | 1 |
| Kerr, SM | 1 |
| Kiess, W | 1 |
| Kleber, ME | 1 |
| Koenig, W | 1 |
| Kooner, JS | 1 |
| Körner, A | 1 |
| Kovacs, P | 1 |
| Krämer, BK | 1 |
| Kronenberg, F | 1 |
| Kubo, M | 1 |
| Kühnel, B | 1 |
| La Bianca, M | 1 |
| Lange, LA | 1 |
| Lehne, B | 1 |
| Lehtimäki, T | 1 |
| Liu, J | 1 |
| Loeffler, M | 1 |
| Loos, RJF | 1 |
| Lyytikäinen, LP | 1 |
| Magi, R | 1 |
| Mahajan, A | 1 |
| Martin, NG | 1 |
| März, W | 1 |
| Mascalzoni, D | 1 |
| Matsuda, K | 1 |
| Meisinger, C | 1 |
| Meitinger, T | 1 |
| Metspalu, A | 1 |
| Milaneschi, Y | 1 |
| O'Donnell, CJ | 1 |
| Wilson, OD | 1 |
| Gaziano, JM | 1 |
| Mishra, PP | 1 |
| Mohlke, KL | 1 |
| Mononen, N | 1 |
| Montgomery, GW | 1 |
| Mook-Kanamori, DO | 1 |
| Müller-Nurasyid, M | 1 |
| Nadkarni, GN | 1 |
| Nalls, MA | 1 |
| Nauck, M | 1 |
| Nikus, K | 1 |
| Ning, B | 1 |
| Nolte, IM | 1 |
| Noordam, R | 1 |
| O'Connell, JR | 1 |
| Olafsson, I | 1 |
| Padmanabhan, S | 1 |
| Penninx, BWJH | 1 |
| Perls, T | 1 |
| Peters, A | 1 |
| Pirastu, M | 1 |
| Pirastu, N | 1 |
| Pistis, G | 1 |
| Polasek, O | 1 |
| Ponte, B | 1 |
| Porteous, DJ | 1 |
| Poulain, T | 1 |
| Preuss, MH | 1 |
| Rabelink, TJ | 1 |
| Raffield, LM | 1 |
| Raitakari, OT | 1 |
| Rettig, R | 1 |
| Rheinberger, M | 1 |
| Rice, KM | 1 |
| Rizzi, F | 1 |
| Robino, A | 1 |
| Rudan, I | 1 |
| Krajcoviechova, A | 1 |
| Cifkova, R | 1 |
| Rueedi, R | 1 |
| Ruggiero, D | 1 |
| Ryan, KA | 1 |
| Saba, Y | 1 |
| Salvi, E | 1 |
| Schmidt, H | 1 |
| Schmidt, R | 1 |
| Shaffer, CM | 1 |
| Smith, AV | 1 |
| Smith, BH | 1 |
| Spracklen, CN | 1 |
| Strauch, K | 1 |
| Stumvoll, M | 1 |
| Sulem, P | 1 |
| Tajuddin, SM | 1 |
| Teren, A | 1 |
| Thiery, J | 1 |
| Thio, CHL | 1 |
| Thorsteinsdottir, U | 1 |
| Toniolo, D | 1 |
| Tönjes, A | 1 |
| Tremblay, J | 1 |
| Uitterlinden, AG | 1 |
| Vaccargiu, S | 1 |
| van der Harst, P | 1 |
| van Duijn, CM | 1 |
| Verweij, N | 1 |
| Völker, U | 1 |
| Vollenweider, P | 1 |
| Waeber, G | 1 |
| Waldenberger, M | 1 |
| Whitfield, JB | 1 |
| Wild, SH | 1 |
| Wilson, JF | 1 |
| Yang, Q | 1 |
| Zhang, W | 2 |
| Zonderman, AB | 1 |
| Bochud, M | 1 |
| Wilson, JG | 1 |
| Pendergrass, SA | 1 |
| Ho, K | 1 |
| Parsa, A | 1 |
| Pramstaller, PP | 1 |
| Psaty, BM | 1 |
| Böger, CA | 1 |
| Snieder, H | 1 |
| Butterworth, AS | 1 |
| Okada, Y | 1 |
| Edwards, TL | 1 |
| Stefansson, K | 1 |
| Susztak, K | 1 |
| Scholz, M | 1 |
| Heid, IM | 1 |
| Hung, AM | 1 |
| Teumer, A | 1 |
| Pattaro, C | 1 |
| Woodward, OM | 1 |
| Vitart, V | 1 |
| Köttgen, A | 1 |
| Wu, D | 1 |
| Lai, X | 1 |
| Li, Q | 1 |
| Sun, L | 1 |
| Chen, R | 1 |
| Sun, S | 2 |
| Cao, F | 1 |
| Furuhashi, M | 1 |
| Eyre, KS | 1 |
| Lewis, F | 1 |
| Cui, H | 1 |
| Grout, E | 1 |
| Mihai, R | 1 |
| Turney, BW | 1 |
| Howles, SA | 1 |
| Zhao, Q | 1 |
| Bi, Y | 1 |
| Guo, J | 1 |
| Liu, YX | 1 |
| Zhong, J | 1 |
| Pan, LR | 1 |
| Tan, Y | 1 |
| Yu, XJ | 1 |
| Huynh, LM | 1 |
| Dianatnejad, S | 1 |
| Tofani, S | 1 |
| Carrillo Ceja, R | 1 |
| Liang, K | 1 |
| Tapiero, S | 1 |
| Jiang, P | 1 |
| Youssef, RF | 1 |
| Son, YB | 1 |
| Yang, JH | 1 |
| Kim, MG | 1 |
| Jo, SK | 1 |
| Cho, WY | 1 |
| Oh, SW | 1 |
| Chu, Y | 1 |
| Huang, Y | 1 |
| Gao, Q | 1 |
| Xie, X | 1 |
| Wang, P | 1 |
| Li, J | 1 |
| He, X | 1 |
| Jiang, Y | 1 |
| Wang, M | 1 |
| Yang, J | 2 |
| Chen, X | 2 |
| Zhou, C | 1 |
| Zhao, Y | 1 |
| Ding, F | 1 |
| Wu, X | 1 |
| Bai, X | 1 |
| Wu, J | 1 |
| Wei, X | 1 |
| Yue, Z | 1 |
| Fang, X | 1 |
| Huang, Q | 1 |
| Wang, Z | 1 |
| Huang, R | 1 |
| Washburn, LK | 1 |
| Nixon, PA | 1 |
| Snively, BM | 1 |
| Russell, GB | 1 |
| Shaltout, HA | 1 |
| South, AM | 1 |
| O'Shea, TM | 1 |
| Silva, CFD | 1 |
| Burgos, MS | 1 |
| Silva, PTD | 1 |
| Burgos, LT | 1 |
| Welser, L | 1 |
| Sehn, AP | 1 |
| Horta, JA | 1 |
| Mello, ED | 1 |
| Reuter, CP | 1 |
| Qin, J | 1 |
| Nan, Q | 1 |
| Yang, R | 1 |
| Debray, FG | 1 |
| Damjanovic, K | 1 |
| Rosset, R | 1 |
| Mittaz-Crettol, L | 1 |
| Roux, C | 1 |
| Braissant, O | 1 |
| Barbey, F | 1 |
| Bonafé, L | 1 |
| De Bandt, JP | 1 |
| Tappy, L | 1 |
| Paquot, N | 1 |
| Tran, C | 1 |
| Kupusinac, A | 1 |
| Doroslovački, R | 1 |
| Malbaški, D | 1 |
| Srdić, B | 1 |
| Stokić, E | 1 |
| Petrie, JL | 1 |
| Patman, GL | 1 |
| Sinha, I | 1 |
| Alexander, TD | 1 |
| Reeves, HL | 1 |
| Agius, L | 1 |
| Elmacı, AM | 1 |
| Ece, A | 1 |
| Akın, F | 1 |
| Stakhova, TIu | 1 |
| Shcherbak, AV | 1 |
| Kozlovskaia, LV | 1 |
| Taranova, MV | 1 |
| Balkarov, IM | 1 |
| Solomenchuk, TN | 1 |
| Semegen-Bodak, KV | 1 |
| Slaba, NA | 1 |
| Chngrian, GV | 1 |
| Mysyshin, MB | 1 |
| Bruun, JM | 1 |
| Maersk, M | 1 |
| Belza, A | 1 |
| Astrup, A | 1 |
| Richelsen, B | 1 |
| Park, JY | 1 |
| Kricka, LJ | 1 |
| Daudon, M | 1 |
| Frochot, V | 1 |
| Rajan, S | 1 |
| Zalpuri, I | 1 |
| Harrington, A | 1 |
| Cimpeanu, C | 1 |
| Song, X | 1 |
| Fan, X | 1 |
| Dornas, WC | 1 |
| de Lima, WG | 1 |
| Pedrosa, ML | 1 |
| Silva, ME | 1 |
| Ohno, I | 1 |
| Krysiak, R | 1 |
| Gilowski, W | 1 |
| Okopień, B | 1 |
| Lee, WJ | 1 |
| Peng, LN | 1 |
| Chiou, ST | 1 |
| Chen, LK | 1 |
| Cambareri, GM | 1 |
| Giel, DW | 1 |
| Bayne, AP | 1 |
| Corbett, S | 1 |
| Schurtz, E | 1 |
| Kovacevic, L | 1 |
| Sukhu, T | 1 |
| Yap, M | 1 |
| Chiang, G | 1 |
| Bevill, M | 1 |
| Kattula, A | 1 |
| Cooper, CS | 1 |
| Storm, DW | 1 |
| Huang, RC | 1 |
| Mori, TA | 1 |
| Burke, V | 1 |
| Newnham, J | 1 |
| Stanley, FJ | 1 |
| Landau, LI | 1 |
| Kendall, GE | 1 |
| Oddy, WH | 1 |
| Beilin, LJ | 1 |
| Mallick, C | 1 |
| De, D | 1 |
| Ghosh, D | 1 |
| Kondo, T | 1 |
| Abe, M | 1 |
| Ueyama, J | 1 |
| Kimata, A | 1 |
| Yamamoto, K | 1 |
| Hori, Y | 1 |
| Alpay, H | 1 |
| Ozen, A | 1 |
| Gokce, I | 1 |
| Biyikli, N | 1 |
| Ahmadi, F | 1 |
| Naseri, R | 1 |
| Lessan-Pezeshki, M | 1 |
| Sepahi, MA | 1 |
| Heidari, A | 1 |
| Shajari, A | 1 |
| Naseri, M | 1 |
| Varasteh, AR | 1 |
| Alamdaran, SA | 1 |
| Tominaga, M | 1 |
| Uno, K | 1 |
| Yagi, K | 1 |
| Fukui, M | 1 |
| Hasegawa, G | 1 |
| Yoshikawa, T | 1 |
| Nakamura, N | 1 |
| Nakumura, N | 1 |
| Hongo, M | 1 |
| Hidaka, H | 1 |
| Sakaguchi, S | 1 |
| Nakanishi, K | 1 |
| Ichikawa, M | 1 |
| Hirota, N | 1 |
| Tanaka, N | 1 |
| Tsuruta, G | 1 |
| Yazaki, Y | 1 |
| Kinoshita, O | 1 |
| Ikeda, U | 1 |
| Koike, K | 1 |
| Roriz, AK | 1 |
| Mello, AL | 1 |
| Guimarães, JF | 1 |
| dos Santos, FC | 1 |
| Medeiros, JM | 1 |
| Sampaio, LR | 1 |
| Chrzczanowicz, J | 1 |
| Gawron-Skarbek, A | 1 |
| Kostka, J | 1 |
| Nowak, D | 1 |
| Drygas, W | 1 |
| Jegier, A | 1 |
| Kostka, T | 1 |
| Puig, JG | 1 |
| Torres, RJ | 1 |
| de Miguel, E | 1 |
| Sánchez, A | 1 |
| Bailén, R | 1 |
| Banegas, JR | 1 |
| Chohan, S | 1 |
| Becker, MA | 2 |
| MacDonald, PA | 1 |
| Chefo, S | 1 |
| Jackson, RL | 1 |
| Lin, JD | 1 |
| Chiou, WK | 1 |
| Weng, HF | 1 |
| Tsai, YH | 1 |
| Liu, TH | 1 |
| BEN-ISHAY, D | 1 |
| DREYFUSS, F | 1 |
| ULLMANN, TD | 1 |
| HAAGENSEN, NR | 1 |
| NIELSEN, B | 1 |
| FRANCOMANERA, R | 1 |
| WATTS, RW | 2 |
| ENGELMAN, K | 1 |
| KLINENBERG, JR | 2 |
| SEEGMILLER, JE | 2 |
| SJOERDSMA, A | 1 |
| PRIOR, IA | 1 |
| ROSE, BS | 1 |
| DAVIDSON, F | 1 |
| BODA, D | 4 |
| HARVEY, AM | 1 |
| CHRISTENSEN, HN | 1 |
| NEEL, JV | 1 |
| RAKIC, MT | 1 |
| DAVIDSON, RT | 1 |
| VALKENBURG, HA | 1 |
| MIKKELSEN, WM | 1 |
| DE JORGE, FB | 1 |
| PAIVA, LJ | 1 |
| MION, D | 1 |
| CINTRA, AB | 1 |
| NOVAR, DA | 1 |
| BOURSIER, B | 1 |
| Komoda, F | 1 |
| Sekine, T | 1 |
| Inatomi, J | 1 |
| Enomoto, A | 1 |
| Endou, H | 1 |
| Ota, T | 1 |
| Matsuyama, T | 1 |
| Ogata, T | 1 |
| Ikeda, M | 1 |
| Awazu, M | 2 |
| Muroya, K | 1 |
| Kamimaki, I | 1 |
| Igarashi, T | 1 |
| Desai, MY | 1 |
| Santos, RD | 1 |
| Dalal, D | 1 |
| Carvalho, JA | 1 |
| Martin, DR | 1 |
| Flynn, JA | 1 |
| Nasir, K | 1 |
| Blumenthal, RS | 1 |
| Nicoletta, JA | 1 |
| Lande, MB | 1 |
| Yamazawa, K | 1 |
| Kodo, K | 1 |
| Maeda, J | 1 |
| Omori, S | 1 |
| Hida, M | 1 |
| Mori, T | 1 |
| Emmerson, BT | 3 |
| Thiele, P | 2 |
| Schröder, HE | 3 |
| Runge, E | 1 |
| Turpin, G | 1 |
| Kuntz, D | 1 |
| Israel, KD | 1 |
| Michaelis, OE | 1 |
| Reiser, S | 1 |
| Keeney, M | 1 |
| Hradec, E | 1 |
| Kocvara, R | 2 |
| Louzenský, G | 2 |
| Revúsová, V | 1 |
| Gratzlová, J | 1 |
| Suchánek, B | 1 |
| Krídl, J | 1 |
| Beck, LH | 1 |
| Giugliani, R | 1 |
| Ferrari, I | 1 |
| Lattanzi, A | 1 |
| Fiegel, G | 1 |
| Heidelmann, G | 2 |
| Schollmeyer, P | 1 |
| Lohse, R | 1 |
| Böhm, WD | 1 |
| Scott, WA | 2 |
| Sorensen, LB | 1 |
| Levinson, DJ | 1 |
| Famaey, JP | 1 |
| Kono, S | 1 |
| Shinchi, K | 1 |
| Imanishi, K | 1 |
| Honjo, S | 1 |
| Todoroki, I | 1 |
| Troillet, N | 1 |
| Gerster, JC | 1 |
| Campoy Martínez, P | 1 |
| Reina Ruiz, C | 1 |
| Salazar Murillo, R | 1 |
| Quintero Rodríguez, R | 1 |
| Espinosa Olmedo, FJ | 1 |
| García Pérez, M | 1 |
| Akaoka, I | 1 |
| Kamatani, N | 2 |
| Albalate, M | 1 |
| de Sequera, P | 1 |
| Vázquez, A | 1 |
| Casado, S | 1 |
| el-Reshaid, K | 1 |
| Mughal, H | 1 |
| Kapoor, M | 1 |
| Iino, Y | 1 |
| Nakanishi, N | 1 |
| Tatara, K | 1 |
| Nakamura, K | 1 |
| Suzuki, K | 1 |
| Finke, D | 1 |
| Tkaczyk, M | 1 |
| Jander, A | 1 |
| Sałacińska, B | 1 |
| Jasińska-Okonek, A | 1 |
| Hulton, SA | 1 |
| Elisaf, M | 1 |
| Kitsos, G | 1 |
| Bairaktari, E | 1 |
| Kalaitzidis, R | 1 |
| Kalogeropoulos, C | 1 |
| Psilas, K | 1 |
| Ishibuchi, S | 1 |
| Morimoto, H | 1 |
| Oe, T | 1 |
| Ikebe, T | 1 |
| Inoue, H | 1 |
| Fukunari, A | 1 |
| Kamezawa, M | 1 |
| Yamada, I | 1 |
| Naka, Y | 1 |
| Kourambas, J | 1 |
| Aslan, P | 1 |
| Teh, CL | 1 |
| Mathias, BJ | 1 |
| Preminger, GM | 1 |
| Martín Hernández, E | 1 |
| Aparicio López, C | 1 |
| Alvarez Calatayud, G | 1 |
| García Herrera, MA | 1 |
| Weinman, EJ | 1 |
| Martin, H | 1 |
| Boulud, B | 1 |
| Martin, C | 1 |
| Romanet, P | 1 |
| Mertz, DP | 3 |
| Lynch, RE | 1 |
| Kjellstrand, CM | 1 |
| Coccia, PF | 1 |
| Fox, IH | 3 |
| Stewart, RB | 1 |
| Yost, RL | 1 |
| Hale, WE | 1 |
| Marks, RG | 1 |
| Schwenke, R | 1 |
| Altus, RE | 1 |
| Kirschner, I | 1 |
| Lowenthal, MN | 1 |
| Dymond, ID | 1 |
| Klein, S | 1 |
| Marré, E | 1 |
| Koza, KD | 1 |
| Sorice, G | 1 |
| Terrizzi, A | 1 |
| Cafiero, F | 1 |
| Pesce, GL | 1 |
| Mellor, D | 1 |
| Raya Muñóz, J | 1 |
| Torres Velasco, F | 1 |
| Beighton, P | 1 |
| Solomon, L | 1 |
| Soskolne, CL | 1 |
| Sweet, MB | 1 |
| Coe, FL | 2 |
| Chanard, J | 1 |
| Kamoun, P | 1 |
| Pleau, JM | 1 |
| Brami, M | 1 |
| Brunois, JP | 1 |
| Funck-Brentano, JL | 1 |
| Germa, D | 1 |
| Blanc, JJ | 1 |
| Boschat, J | 1 |
| Granatelli, D | 1 |
| Penther, P | 1 |
| de Graciansky, P | 1 |
| Larrégue, M | 1 |
| Martinet, C | 1 |
| Laing, JK | 2 |
| King, WH | 1 |
| Lancaster, MC | 1 |
| Cloyd, DE | 1 |
| Potaux, L | 1 |
| Aparicio, M | 1 |
| Maurel, C | 1 |
| Ruedas, ME | 1 |
| Martin-Dupont, Cl | 1 |
| Dubovsky, D | 1 |
| Jacobs, P | 1 |
| Malek, RS | 1 |
| Kelalis, PP | 1 |
| Dosman, JA | 1 |
| Crawhall, JC | 1 |
| Klassen, GA | 1 |
| Monaco, G | 1 |
| Eleuteri, E | 1 |
| Coppola, M | 1 |
| Lorentz, C | 1 |
| Silvestri, A | 1 |
| Ciulli, A | 1 |
| Vendl, L | 2 |
| Chanteclair, G | 1 |
| Olive, D | 1 |
| Doury, P | 1 |
| Delahaye, RP | 1 |
| Leguay, G | 1 |
| Pattin, S | 1 |
| Metges, PJ | 1 |
| Montely, JM | 1 |
| Duret, JC | 1 |
| Salhi, A | 1 |
| Procaccio, P | 1 |
| Pirrelli, A | 1 |
| Carcassi, A | 1 |
| Naess, K | 1 |
| Thomas, CR | 1 |
| Dodhia, N | 1 |
| Nagy, F | 1 |
| Baldree, LA | 1 |
| Stapleton, FB | 1 |
| Seftel, A | 1 |
| Resnick, MI | 1 |
| Ptácek, V | 1 |
| Patterson, KL | 1 |
| Klopovich, P | 1 |
| Menghini, S | 1 |
| Della Corte, E | 1 |
| Kojima, T | 1 |
| Nishina, T | 1 |
| Kitamura, M | 1 |
| Nishioka, K | 1 |
| Raisen, L | 1 |
| Smith, LH | 1 |
| Leighton, PW | 1 |
| Babucke, G | 1 |
| Burmeister, H | 1 |
| Ohlmeier, H | 1 |
| Baethke, R | 1 |
| Wegienka, LC | 1 |
| Simpson, RG | 1 |
| Karam, JH | 1 |
| Forsham, PH | 1 |
| Frank, O | 1 |
| Riley, MJ | 1 |
| Allwright, GT | 1 |
| Ibrahim, SA | 1 |
| Johnson, ES | 1 |
| Garrick, R | 1 |
| Ewan, CE | 1 |
| Bauer, GE | 1 |
| Neale, FC | 1 |
| Blacket, RB | 1 |
| Leelarthaepin, B | 1 |
| Palmer, AJ | 1 |
| Woodhill, JM | 1 |
| Transbol, I | 1 |
| Frydendal, N | 1 |
| Murray, JT | 1 |
| Vincent, PC | 1 |
| Gunz, FW | 1 |
| Levi, JA | 1 |
| Bailey, RR | 1 |
| Dann, E | 1 |
| Greenslade, NF | 1 |
| Little, PJ | 1 |
| McRae, CU | 1 |
| Utley, WL | 1 |
| Scott, JT | 5 |
| Gross, A | 1 |
| Girard, V | 1 |
| Delbarre, F | 2 |
| de Gery, A | 1 |
| Kelley, WN | 1 |
| Grobner, W | 1 |
| Holmes, E | 1 |
| Dumas, R | 1 |
| Castel, J | 1 |
| Jean, R | 1 |
| Hagler, L | 1 |
| Herman, RH | 1 |
| O'Sullivan, WJ | 1 |
| Brogard, JM | 1 |
| Coumaros, D | 1 |
| Franckhauser, J | 1 |
| Stahl, A | 1 |
| Stahl, J | 1 |
| Clarke, GR | 1 |
| Roux, H | 2 |
| Vovan, L | 2 |
| Dutertre, P | 2 |
| Serratrice, G | 2 |
| Recordier, AM | 2 |
| Fischer, V | 1 |
| Dietschi, C | 1 |
| Bluestone, R | 1 |
| Schlosstein, L | 1 |
| Waisman, J | 1 |
| Whitehouse, MW | 1 |
| Garijo Forcada, JM | 1 |
| Aguado Pérez, M | 1 |
| Fairley, KF | 1 |
| Whitworth, JA | 1 |
| Radford, NJ | 1 |
| Butler, HM | 1 |
| Kay, NE | 1 |
| Gottlieb, AJ | 1 |
| Rondier, J | 1 |
| Cayla, J | 1 |
| Tiso, B | 1 |
| Herrlein, A | 1 |
| Kuntzinger, H | 1 |
| Thier, SO | 1 |
| Wessler, S | 1 |
| Avioli, LV | 1 |
| Radi, I | 1 |
| Heuckenkamp, PU | 1 |
| Schill, K | 1 |
| Zöllner, N | 3 |
| Barnes, CG | 1 |
| Láhoda, F | 1 |
| Ross, A | 1 |
| Paulson, DF | 1 |
| Glenn, JF | 1 |
| Hughes, J | 1 |
| Roberts, LC | 1 |
| Coppridge, AJ | 1 |
| Jeremy, R | 1 |
| Fessel, WJ | 1 |
| Zöllner, R | 1 |
| Fedorova, NI | 1 |
| Tsisliak, VV | 1 |
| Tanabe, Y | 1 |
| Grancharov, V | 1 |
| Hansen, OE | 1 |
| Appleyard, WJ | 1 |
| Martin, DJ | 1 |
| Jaffe, N | 1 |
| Storti, E | 1 |
| Quaglino, D | 1 |
| Healey, LA | 1 |
| Harkness, RA | 1 |
| Nicol, AD | 1 |
| Adolphs, HD | 1 |
| Irmscher, K | 1 |
| Solbach, HG | 1 |
| Kutter, D | 1 |
| Humbel, R | 1 |
| Bisdorff, J | 1 |
| Drach, GW | 1 |
| Smith, MJ | 1 |
| Boyce, WH | 1 |
| Penzes, P | 1 |
| Gecse, A | 1 |
| Streitmann, K | 1 |
| Zsilnszky, E | 1 |
| Karady, I | 1 |
| Van Goor, W | 1 |
| Kooiker, CJ | 1 |
| Mees, EJ | 1 |
| Nyhan, WL | 1 |
| Sweetman, L | 1 |
| Carpenter, DG | 1 |
| Carter, CH | 1 |
| Hoefnagel, D | 1 |
| Krakoff, IH | 1 |
| Murphy, ML | 1 |
| Grahame, R | 1 |
| Haslam, RM | 1 |
| Wada, Y | 1 |
| Arakawa, T | 1 |
| Koizumi, K | 1 |
| Haim, S | 1 |
| Gellei, B | 1 |
| Better, OS | 1 |
| Borgno, M | 1 |
| Marten Perolino, R | 1 |
| Kaplan, D | 1 |
| Diamond, H | 1 |
| Wallace, SL | 1 |
| Halberstam, D | 1 |
| Pearce, J | 1 |
| Aziz, H | 1 |
| Kelbel, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Study of the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders[NCT06092346] | 999 participants (Anticipated) | Observational | 2024-01-03 | Recruiting | |||
| Are Heterozygous Carriers for Hereditary Fructose Intolerance Predisposed to Metabolic Disturbances When Exposed to Fructose?[NCT02979106] | 18 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Effect of Carbonated Soft Drinks on Body Weight, Fat Distribution and Metabolic Risk Factors[NCT00777647] | 60 participants (Actual) | Interventional | 2008-05-31 | Completed | |||
| Hypomagnesemia and Its Association With Calcineurin Inhibitors Use in Egyptian Renal Transplant Recipients[NCT05352880] | 80 participants (Actual) | Interventional | 2022-05-10 | Completed | |||
| A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.[NCT00174915] | Phase 3 | 1,072 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.[NCT00430248] | Phase 3 | 2,269 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout[NCT00102440] | Phase 3 | 760 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in number of tophi/subject was calculated for the subset of subjects with palpable tophi at the Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks)
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Febuxostat 240 mg QD | 0.0 |
| Allopurinol QD | 0.0 |
| Placebo QD | 0.0 |
Change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were not palpable at the Week 28 visit, the total count was assumed to be 0. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Febuxostat 240 mg QD | 0.0 |
| Allopurinol QD | 0.0 |
| Placebo QD | 0.0 |
The percent change in serum urate from baseline to the Final visit was summarized. The percent change in serum urate was calculated as [(Final visit - baseline levels)/baseline]*100. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)
| Intervention | Percent change (Mean) |
|---|---|
| Febuxostat 80 mg QD | -45.2 |
| Febuxostat 120 mg QD | -51.9 |
| Febuxostat 240 mg QD | -66.3 |
| Allopurinol QD | -33.7 |
| Placebo QD | -3.0 |
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(Week 28 - baseline levels)/baseline]*100 and summarized. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | Percent change (Mean) |
|---|---|
| Febuxostat 80 mg QD | -47.6 |
| Febuxostat 120 mg QD | -54.9 |
| Febuxostat 240 mg QD | -67.8 |
| Allopurinol QD | -34.4 |
| Placebo QD | -3.6 |
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00174915)
Timeframe: Baseline and Final Visit (up to 28 weeks)
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -33.8 |
| Febuxostat 120 mg QD | -42.4 |
| Febuxostat 240 mg QD | -47.0 |
| Allopurinol QD | -22.6 |
| Placebo QD | -40.3 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00174915)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -45.6 |
| Febuxostat 120 mg QD | -54.2 |
| Febuxostat 240 mg QD | -53.2 |
| Allopurinol QD | -31.5 |
| Placebo QD | -52.0 |
Percentage of subjects requiring treatment for a gout flare between Weeks 8 and 28 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00174915)
Timeframe: Weeks 8 through 28
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 55 |
| Febuxostat 120 mg QD | 54 |
| Febuxostat 240 mg QD | 57 |
| Allopurinol QD | 46 |
| Placebo QD | 52 |
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00174915)
Timeframe: Last 3 visits (any last 3 visits up to week 28)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 48 |
| Febuxostat 120 mg QD | 65 |
| Febuxostat 240 mg QD | 69 |
| Allopurinol QD | 22 |
| Placebo QD | 0 |
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected and may have differed by subject. (NCT00174915)
Timeframe: Final Visit (up to 28 weeks).
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 72 |
| Febuxostat 120 mg QD | 79 |
| Febuxostat 240 mg QD | 92 |
| Allopurinol QD | 39 |
| Placebo QD | 1 |
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00174915)
Timeframe: Week 28
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 76 |
| Febuxostat 120 mg QD | 87 |
| Febuxostat 240 mg QD | 94 |
| Allopurinol QD | 41 |
| Placebo QD | 1 |
The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Baseline and Last Visit on treatment (up to 6 months)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -33.1 |
| Febuxostat 80 mg QD | -40.6 |
| Allopurinol 200 mg or 300 mg QD | -31.3 |
Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 2
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.1 |
| Febuxostat 80 mg QD | -44.5 |
| Allopurinol 200 mg or 300 mg QD | -33.8 |
Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 4
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -34.9 |
| Febuxostat 80 mg QD | -45.5 |
| Allopurinol 200 mg or 300 mg QD | -34.5 |
Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized. (NCT00430248)
Timeframe: Baseline and Month 6
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 40 mg QD | -35.6 |
| Febuxostat 80 mg QD | -45.1 |
| Allopurinol 200 mg or 300 mg QD | -34.4 |
The percentage of subjects with mild-to-moderate renal impairment whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 49.7 |
| Febuxostat 80 mg QD | 71.6 |
| Allopurinol 200 mg or 300 mg QD | 42.3 |
The percentage of subjects whose serum urate level was <6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 45.2 |
| Febuxostat 80 mg QD | 67.1 |
| Allopurinol 200 mg or 300 mg QD | 42.1 |
The percentage of subjects whose serum urate level was <4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.5 |
| Febuxostat 80 mg QD | 17.5 |
| Allopurinol 200 mg or 300 mg QD | 1.5 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.1 |
| Febuxostat 80 mg QD | 17.5 |
| Allopurinol 200 mg or 300 mg QD | 1.5 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 2.0 |
| Febuxostat 80 mg QD | 18.6 |
| Allopurinol 200 mg or 300 mg QD | 1.4 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <4.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 3.1 |
| Febuxostat 80 mg QD | 20.3 |
| Allopurinol 200 mg or 300 mg QD | 1.8 |
The percentage of subjects whose serum urate level was <5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected. (NCT00430248)
Timeframe: Last Visit on treatment (up to 6 months)
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 16.5 |
| Febuxostat 80 mg QD | 44.0 |
| Allopurinol 200 mg or 300 mg QD | 13.2 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 15.4 |
| Febuxostat 80 mg QD | 45.9 |
| Allopurinol 200 mg or 300 mg QD | 11.7 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 15.0 |
| Febuxostat 80 mg QD | 51.6 |
| Allopurinol 200 mg or 300 mg QD | 13.5 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <5.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 19.3 |
| Febuxostat 80 mg QD | 49.7 |
| Allopurinol 200 mg or 300 mg QD | 14.8 |
Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 2 visit was summarized. (NCT00430248)
Timeframe: Month 2
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 49.1 |
| Febuxostat 80 mg QD | 74.1 |
| Allopurinol 200 mg or 300 mg QD | 43.2 |
Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 4 visit was summarized. (NCT00430248)
Timeframe: Month 4
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 40 mg QD | 47.1 |
| Febuxostat 80 mg QD | 75.2 |
| Allopurinol 200 mg or 300 mg QD | 45.5 |
Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 6 visit was summarized. (NCT00430248)
Timeframe: Month 6
| Intervention | percentage of participants (Number) |
|---|---|
| Febuxostat 40 mg QD | 48.9 |
| Febuxostat 80 mg QD | 75.3 |
| Allopurinol 200 mg or 300 mg QD | 46.6 |
Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Allopurinol 300 mg QD | 0.0 |
The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | 0.0 |
| Allopurinol 300 mg QD | 0.0 |
The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | number of tophi (Median) |
|---|---|
| Febuxostat 80 mg QD | 0.0 |
| Febuxostat 120 mg QD | -1.0 |
| Allopurinol 300 mg QD | 0.0 |
The percent change in serum urate from baseline to the Final visit was calculated as [(Final Visit - baseline levels/baseline)]*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -44.7 |
| Febuxostat 120 mg QD | -51.5 |
| Allopurinol 300 mg QD | -33.0 |
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(week 28 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -46.3 |
| Febuxostat 120 mg QD | -53.5 |
| Allopurinol 300 mg QD | -34.8 |
Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as [(week 52 - baseline levels/baseline)]*100 and summarized. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | percent change from baseline (Mean) |
|---|---|
| Febuxostat 80 mg QD | -47.7 |
| Febuxostat 120 mg QD | -53.0 |
| Allopurinol 300 mg QD | -34.8 |
Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Baseline and Final Visit (up to 52 weeks)
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -51.7 |
| Febuxostat 120 mg QD | -43.8 |
| Allopurinol 300 mg QD | -39.6 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 28
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -29.5 |
| Febuxostat 120 mg QD | -49.5 |
| Allopurinol 300 mg QD | -28.6 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 52 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero. (NCT00102440)
Timeframe: Baseline and Week 52
| Intervention | percent change from baseline (Median) |
|---|---|
| Febuxostat 80 mg QD | -83.4 |
| Febuxostat 120 mg QD | -65.5 |
| Allopurinol 300 mg QD | -49.7 |
The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once. (NCT00102440)
Timeframe: Weeks 8 through 52
| Intervention | percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 64 |
| Febuxostat 120 mg QD | 70 |
| Allopurinol 300 mg QD | 64 |
The percentage of subjects whose serum urate was <6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject. (NCT00102440)
Timeframe: Final Visit (up to 52 weeks)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 74 |
| Febuxostat 120 mg QD | 80 |
| Allopurinol 300 mg QD | 36 |
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 28 visit was summarized. (NCT00102440)
Timeframe: Week 28
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 72 |
| Febuxostat 120 mg QD | 82 |
| Allopurinol 300 mg QD | 42 |
Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Week 52 visit was summarized. (NCT00102440)
Timeframe: Week 52
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 81 |
| Febuxostat 120 mg QD | 82 |
| Allopurinol 300 mg QD | 39 |
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject. (NCT00102440)
Timeframe: Last 3 Visits (up to 52 weeks)
| Intervention | Percentage of subjects (Number) |
|---|---|
| Febuxostat 80 mg QD | 53 |
| Febuxostat 120 mg QD | 62 |
| Allopurinol 300 mg QD | 21 |
26 reviews available for uric acid and Metabolic Diseases
| Article | Year |
|---|---|
Regulation of Catechins in Uric Acid Metabolism Disorder Related Human Diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Catechin; Humans; Metabolic Diseases; Uric Ac | 2020 |
New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Topics: Biomarkers; Humans; Metabolic Diseases; Purines; Reactive Oxygen Species; Uric Acid; Xanthine Dehydr | 2020 |
Metabolic diagnoses of recurrent stone formers: temporal, geographic and gender differences.
Topics: Citric Acid; Female; Global Health; Humans; Hypercalciuria; Hyperoxaluria; Kidney Calculi; Male; Met | 2020 |
Crystalluria.
Topics: Biomarkers; Calcium Oxalate; Calcium Phosphates; Crystallization; Humans; Metabolic Diseases; Micros | 2015 |
Health implications of high-fructose intake and current research.
Topics: Animals; Diet; Dietary Sucrose; Fructose; Humans; Hypertension; Hypertriglyceridemia; Insulin; Insul | 2015 |
[Kidney diseases and metabolic disorders--basics and applications required for general physicians. Topics: IV. Uric acid metabolic disorder (relationship between liyperuricemia and CKD-CVD)].
Topics: Age Factors; Animals; Cardiovascular Diseases; General Practitioners; Humans; Kidney Diseases; Metab | 2015 |
[DISEASES OF THE METABOLISM OF PURINES AND PYRIMIDINES].
Topics: Gout; Humans; Metabolic Diseases; Orotic Acid; Purines; Pyrimidines; Uric Acid; Urine; Xanthines | 1963 |
Medical evaluation and treatment of urolithiasis.
Topics: Adolescent; Calcium Metabolism Disorders; Child; Child, Preschool; Cystinuria; Humans; Hyperoxaluria | 2006 |
[Pathogenesis and therapy of nitrogen catabolism disorders: hyperazotemia versus hyperammonemia versus hyperuricemia].
Topics: Ammonia; Humans; Metabolic Diseases; Nitrogen; Purines; Pyrimidines; Uric Acid | 1981 |
[Abnormalities in urate metabolism: concept and classification].
Topics: Adult; Animals; Humans; Hypoxanthine Phosphoribosyltransferase; Male; Metabolic Diseases; Mutation; | 1996 |
[Metabolic tubulo-interstitial nephropathies].
Topics: Cystinuria; Humans; Metabolic Diseases; Nephritis, Interstitial; Oxalates; Uric Acid | 1999 |
Evaluation of urinary tract calculi in children.
Topics: Calcium; Child; Child, Preschool; Cystine; Female; Hematuria; Humans; Kidney Calculi; Magnesium Comp | 2001 |
[Theory of pathogenesis in primary hyperuricamia].
Topics: Adenosine Monophosphate; Adult; Child; Female; Glucosephosphates; Glycine; Gout; Humans; Kidney; Les | 1975 |
Renal and metabolic complications of childhood non-Hodgkin's lymphoma.
Topics: Acidosis; Acute Kidney Injury; Allopurinol; Aluminum Hydroxide; Burkitt Lymphoma; Child; Humans; Hyp | 1977 |
Encephalitis and encephalopathy in childhood leukaemia.
Topics: Antineoplastic Agents; Asparaginase; Brain Diseases; Brain Neoplasms; Child; Encephalitis; Humans; L | 1976 |
[Metabolism and physiopathology of uric acid].
Topics: Blood Proteins; Chemical Phenomena; Chemistry; Humans; Kidney Glomerulus; Metabolic Diseases; Protei | 1976 |
Common emergencies in cancer medicine: metabolic syndromes.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adrenal Cortex Diseases; Emergencies; Humans; Hypercalcemia; | 1991 |
Metabolic evaluation of urolithiasis.
Topics: Calcium; Cystine; Humans; Magnesium; Magnesium Compounds; Metabolic Diseases; Phosphates; Struvite; | 1990 |
Pyrimidine metabolism in man.
Topics: Amidohydrolases; Aminoisobutyric Acids; Aspartate Carbamoyltransferase; Bacteria; Carboxy-Lyases; Cy | 1973 |
[Gout, archetype of diseases caused by deposits].
Topics: Gout; Humans; Kidney Calculi; Kinins; Lesch-Nyhan Syndrome; Metabolic Diseases; Nephritis, Interstit | 1972 |
Current concepts in the pathogenesis of hyperuricemia.
Topics: Gout; Humans; Metabolic Diseases; Purine Nucleotides; Purines; Uric Acid | 1973 |
Oxalate metabolism. IV.
Topics: Animals; Calcinosis; Calcium; Ethylenes; Glycols; Humans; Kidney Calculi; Kidney Diseases; Metabolic | 1973 |
Orotic acid.
Topics: Allopurinol; Anemia, Pernicious; Animals; Azauridine; Carboxy-Lyases; Fatty Liver; Female; Humans; I | 1973 |
Purine ribonucleotide catabolism: clinical and biochemical significance. Review.
Topics: Adenosine Triphosphate; Allopurinol; Animals; Carbohydrate Metabolism, Inborn Errors; Fructose; Huma | 1974 |
Genetic aspects of gout.
Topics: Adenine; Allopurinol; Carbon Radioisotopes; Erythrocytes; Fibroblasts; Glucosephosphate Dehydrogenas | 1974 |
[Gout].
Topics: Allopurinol; Chondrocalcinosis; Colchicine; Diagnosis, Differential; Diet Therapy; Gout; Humans; Ino | 1970 |
10 trials available for uric acid and Metabolic Diseases
| Article | Year |
|---|---|
Are heterozygous carriers for hereditary fructose intolerance predisposed to metabolic disturbances when exposed to fructose?
Topics: Adult; Carbohydrate Metabolism; Creatinine; Female; Fructose; Fructose Intolerance; Heterozygote; Hu | 2018 |
Consumption of sucrose-sweetened soft drinks increases plasma levels of uric acid in overweight and obese subjects: a 6-month randomised controlled trial.
Topics: Adult; Animals; Carbonated Beverages; Dietary Sucrose; Drinking Water; Female; Humans; Insulin; Live | 2015 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febux | 2012 |
Role of hyperuricaemia in critically ill patients especially newborns.
Topics: Acute Disease; Age Factors; Allopurinol; Animals; Child; Clinical Trials as Topic; Humans; Infant; I | 1984 |
[Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibrate; Female; Humans; Hy | 1982 |
[Forestier disease and metabolism disorders. A prospective controlled study of 25 cases].
Topics: Adult; Aged; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyper | 1993 |
[Uricolytic therapy. Value of urate oxidase in the treatment of hyperuricemias].
Topics: Acute Kidney Injury; Adult; Aged; Allantoin; Chemical Phenomena; Chemistry; Clinical Trials as Topic | 1975 |
Use of Rabenid for different indications.
Topics: Adult; Aged; Female; Humans; Male; Metabolic Diseases; Middle Aged; Sulfinpyrazone; Uric Acid | 1991 |
[Effect of benzbromarone in uricemia and uricosuria].
Topics: Aspirin; Benzofurans; Chlorothiazide; Clinical Trials as Topic; Colchicine; Drug Combinations; Human | 1972 |
[Urate oxidase in pediatrics].
Topics: Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Female; Humans; Kidney Failure, Chron | 1973 |
178 other studies available for uric acid and Metabolic Diseases
| Article | Year |
|---|---|
Autonomic dysfunction and metabolic disorders as the possible sequelae of COVID-19 infection.
Topics: Autonomic Nervous System Diseases; Blood Pressure Monitoring, Ambulatory; COVID-19; Exercise Test; F | 2022 |
Nanozymatic magnetic nanomixers for enzyme immobilization and multiplexed detection of metabolic disease biomarkers.
Topics: Antioxidants; Biomarkers; Biosensing Techniques; Cholesterol; Colorimetry; Enzymes, Immobilized; Glu | 2023 |
Prevalence and risk factors of hyperuricaemia in non-obese Chinese: a single-centre cross-sectional study.
Topics: Adult; Body Mass Index; China; Cross-Sectional Studies; East Asian People; Female; Humans; Hyperuric | 2022 |
Pseudohypoadrenalism, a subclinical cortisol metabolism disorder in hyperuricemia.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Bile Acids and Salts; Humans; Hydrocortisone; Hyperu | 2023 |
Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiovascular Diseases; Cohort Studies; Ge | 2019 |
Utility of blood tests in screening for metabolic disorders in kidney stone disease.
Topics: Acidosis, Renal Tubular; Adult; Aged; Aged, 80 and over; Bicarbonates; Calcium; Chlorides; Female; H | 2021 |
Pristimerin protects against inflammation and metabolic disorder in mice through inhibition of NLRP3 inflammasome activation.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Inflammasomes; Inflammation; Lipopolysaccharides | 2021 |
The effect of baseline serum uric acid on chronic kidney disease in normotensive, normoglycemic, and non-obese individuals: A health checkup cohort study.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Cohort Studies; Diabetes Mellitus; Female; Glomerular | 2021 |
Metagenomic analysis revealed the potential role of gut microbiome in gout.
Topics: Adolescent; Adult; Aged; Arthritis; Bacteria; Butyrates; Diabetes Mellitus, Type 2; Dysbiosis; Fatty | 2021 |
Antenatal corticosteroids and cardiometabolic outcomes in adolescents born with very low birth weight.
Topics: Adolescent; Adrenal Cortex Hormones; Biomarkers; Birth Weight; Blood Pressure; Body Composition; C-R | 2017 |
Relationship between Cardiometabolic Parameters and Elevated Resting and Effort Heart Rate in Schoolchildren.
Topics: Adolescent; Biomarkers; Blood Pressure; Child; Cross-Sectional Studies; Female; Glycemic Index; Hear | 2017 |
Bright carbon dots via inner filter effect for the sensitive determination of the purine metabolic disorder in human fluids.
Topics: Body Fluids; Carbon; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Metabolic Diseases; Purin | 2018 |
A primary estimation of the cardiometabolic risk by using artificial neural networks.
Topics: Adolescent; Adult; Age Factors; Aged; Atherosclerosis; Blood Pressure; Body Mass Index; Female; Fibr | 2013 |
The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis.
Topics: Adenosine Triphosphate; Animals; Biomarkers; Cells, Cultured; Health Status Indicators; Hep G2 Cells | 2013 |
Clinical characteristics and metabolic abnormalities in preschool-age children with urolithiasis in southeast Anatolia.
Topics: Biomarkers; Calcium Oxalate; Calcium Phosphates; Child; Child, Preschool; Cysteine; Female; Follow-U | 2014 |
[Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorder
Topics: Albuminuria; beta 2-Microglobulin; Biomarkers; Chemokine CCL2; Comorbidity; Endothelin-1; Endotheliu | 2014 |
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease | 2014 |
Extreme clinical chemistry.
Topics: Biomarkers; Chemistry, Clinical; Humans; Metabolic Diseases; Neoplasms; Serum Albumin; Tangier Disea | 2015 |
Relationship between serum uric acid level and cardiometabolic risks in nondiabetic patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cross-Sectional Stu | 2016 |
The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism.
Topics: Aged; Atorvastatin; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Drug Th | 2016 |
Relative Handgrip Strength Is a Simple Indicator of Cardiometabolic Risk among Middle-Aged and Older People: A Nationwide Population-Based Study in Taiwan.
Topics: Aged; Anthropometry; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cholestero | 2016 |
Do Overweight and Obese Pediatric Stone Formers Have Differences in Metabolic Abnormalities Compared With Normal-weight Stone Formers?
Topics: Adolescent; Biomarkers; Body Mass Index; Child; Creatinine; Female; Follow-Up Studies; Humans; Kidne | 2017 |
The Modern Metabolic Stone Evaluation in Children.
Topics: Adolescent; Biomarkers; Calcium; Child; Child, Preschool; Disease Progression; Female; Follow-Up Stu | 2017 |
Synergy between adiposity, insulin resistance, metabolic risk factors, and inflammation in adolescents.
Topics: Adolescent; Alanine Transaminase; Australia; C-Reactive Protein; Cardiovascular Diseases; Cholestero | 2009 |
Correction of protein metabolic disorders by composite extract of Musa paradisiaca and Coccinia indica in streptozotocin-induced diabetic albino rat: an approach through the pancreas.
Topics: Amidohydrolases; Animals; Blood Glucose; Cucurbitaceae; Diabetes Mellitus, Experimental; Glycated He | 2009 |
Use of waist circumference and ultrasonographic assessment of abdominal fat distribution in predicting metabolic risk factors in healthy Japanese adults.
Topics: Abdominal Fat; Adult; Aged; Asian People; Blood Glucose; Female; Humans; Hypertension; Lipids; Male; | 2009 |
Clinical and metabolic features of urolithiasis and microlithiasis in children.
Topics: Calcium; Child; Child, Preschool; Citric Acid; Cystinuria; Female; Humans; Hypercalciuria; Hyperoxal | 2009 |
Relation of magnesium level to cyclosporine and metabolic complications in renal transplant recipients.
Topics: Adult; Biomarkers; Blood Glucose; Creatinine; Cross-Sectional Studies; Cyclosporine; Female; Graft R | 2009 |
Clinical manifestations and etiology of renal stones in children less than 14 years age.
Topics: Adolescent; Child; Child, Preschool; Citric Acid; Cystinuria; Dysuria; Female; Fever; Genetic Predis | 2010 |
Metabolic factors associated with urinary calculi in children.
Topics: Adolescent; Calcium; Child; Child, Preschool; Citric Acid; Cystinuria; Female; Humans; Hypercalciuri | 2010 |
Association between capacity of interferon-alpha production and metabolic parameters.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Disease Susceptibility; Female; Humans; Hyperglycemia; | 2010 |
Association between serum uric acid levels and cardiometabolic risk factors among Japanese junior high school students.
Topics: Adolescent; Asian People; Dyslipidemias; Female; Heart Diseases; Humans; Hypertension; Male; Metabol | 2010 |
Imaging assessment of visceral adipose tissue area and its correlations with metabolic alterations.
Topics: Adult; Aged; Blood Glucose; Cross-Sectional Studies; Female; Humans; Intra-Abdominal Fat; Lipids; Ma | 2010 |
Physical activity and total antioxidant capacity across an adult lifespan of men.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cardiovascular Diseases; Humans; Lipids; Longevity; M | 2012 |
Uric acid excretion in healthy subjects: a nomogram to assess the mechanisms underlying purine metabolic disorders.
Topics: Adult; Creatinine; Humans; Male; Metabolic Diseases; Middle Aged; Nomograms; Purines; Statistics, No | 2012 |
Comparison of three-dimensional anthropometric body surface scanning to waist-hip ratio and body mass index in correlation with metabolic risk factors.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Composition; B | 2002 |
Fanconi syndrome with hypouricemia in an adult: family study.
Topics: Adult; Fanconi Syndrome; Humans; Medical Records; Metabolic Diseases; Uric Acid; Water-Electrolyte I | 1961 |
The effect of probenecid on renal excretion and plasma level of uric acid in patients with renal insufficiency.
Topics: Humans; Kidney; Kidney Diseases; Metabolic Diseases; Probenecid; Renal Elimination; Renal Insufficie | 1961 |
ENZYME DEFECT IN A CASE OF XANTHINURIA.
Topics: Biopsy; Blood Chemical Analysis; Carbon Isotopes; Child; Electrophoresis; Humans; Hypogonadism; Jeju | 1964 |
METABOLIC MALADIES IN NEW ZEALAND MAORIS.
Topics: Adolescent; Anthropometry; Blood Chemical Analysis; Cholesterol; Coronary Disease; Epidemiology; Eth | 1964 |
[DISEASES OF THE INTRACELLULAR SYSTEM IN THE COURSE OF ACUTE METABOLIC DISTURBANCES].
Topics: Blood Chemical Analysis; Cell Biology; Hypernatremia; Hypokalemia; Metabolic Diseases; Nitrogen; Sep | 1964 |
URIC ACID TRANSPORT SYSTEM: APPARENT ABSENCE IN ERYTHROCYTES OF THE DALMATIAN COACH HOUND.
Topics: Animals; Biological Transport; Carbon Isotopes; Dogs; Erythrocytes; Genetics; Hypoxanthines; Immunol | 1964 |
STUDIES ON HYPERURICEMIA. II. A RECONSIDERATION OF THE DISTRIBUTION OF SERUM URIC ACID VALUES IN THE FAMILIES OF SMYTH, COTTERMAN, AND FREYBERG.
Topics: Blood; Genetics, Medical; Genetics, Population; Gout; Humans; Hyperuricemia; Metabolic Diseases; Mol | 1965 |
SOME BIOCHEMICAL FINDINGS IN OTOSCLEROSIS.
Topics: Alkaline Phosphatase; Blood; Calcium; Chlorine; Cholesterol; Copper; Humans; Magnesium; Metabolic Di | 1965 |
[OVER-EXERTION AND METABOLIC DISORDERS].
Topics: Balneology; Blood; Catalase; Fatigue; Humans; Hyperlipidemias; Hypertension; Liver; Metabolic Diseas | 1965 |
The W258X mutation in SLC22A12 is the predominant cause of Japanese renal hypouricemia.
Topics: Adolescent; Adult; Carrier Proteins; Child; Child, Preschool; Exons; Female; Humans; Introns; Japan; | 2004 |
Relation of serum uric acid with metabolic risk factors in asymptomatic middle-aged Brazilian men.
Topics: Adult; Age Factors; Brazil; Cardiovascular Diseases; Cholesterol, HDL; Cross-Sectional Studies; Huma | 2005 |
Hyponatremia, hypophosphatemia, and hypouricemia in a girl with macrophage activation syndrome.
Topics: Female; Humans; Hyponatremia; Hypophosphatemia; Infant; Macrophage Activation; Metabolic Diseases; S | 2006 |
The use of the xanthine oxidase inhibitor, allopurinol, in the control of hyperuricaemia, gout and uric acid calculi.
Topics: Adult; Aged; Allopurinol; Female; Gout; Humans; Hypoxanthines; Male; Metabolic Diseases; Middle Aged | 1967 |
[The treatment of essential hyperuricemia in graduated programs].
Topics: Combined Modality Therapy; Diet Therapy; Female; Humans; Male; Metabolic Diseases; Purines; Uric Aci | 1984 |
[Metabolic disorders in hyperuricemia].
Topics: Diabetes Mellitus; Glycerides; Gout; Humans; Metabolic Diseases; Obesity; Uric Acid | 1983 |
[Should asymptomatic hyperuricemia be treated?].
Topics: Gout; Humans; Metabolic Diseases; Uric Acid | 1983 |
Serum uric acid, inorganic phosphorus, and glutamic-oxalacetic transaminase and blood pressure in carbohydrate-sensitive adults consuming three different levels of sucrose.
Topics: Adult; Aspartate Aminotransferases; Blood Pressure; Dietary Carbohydrates; Female; Humans; Male; Met | 1983 |
[Occurrence of metabolic disorders in relation to the clinical severity of urolithiasis].
Topics: Adolescent; Adult; Aged; Calcium; Female; Humans; Male; Metabolic Diseases; Middle Aged; Oxalates; U | 1984 |
[Advances in the diagnosis, treatment and prevention of the metabolic causes of urolithiasis].
Topics: Humans; Magnesium; Metabolic Diseases; Oxalates; Uric Acid; Urinary Calculi | 1984 |
Clinical disorders of uric acid metabolism.
Topics: Amidophosphoribosyltransferase; Diet; Gout; Humans; Hypoxanthine Phosphoribosyltransferase; Kidney; | 1981 |
[Management of multiple metabolic overcharge].
Topics: Diet; Humans; Hyperglycemia; Hyperlipidemias; Metabolic Diseases; Uric Acid | 1980 |
[A schedule for the detection of metabolic disorders in subjects with urolithiasis].
Topics: Calcium; Humans; Metabolic Diseases; Oxalates; Uric Acid; Urinary Calculi | 1981 |
[Prevention and therapy of disorders of purine metabolism].
Topics: Arteriosclerosis; Diabetes Mellitus; Gout; Gout Suppressants; Humans; Hyperlipoproteinemias; Metabol | 1982 |
[Interstitial nephritis in metabolic diseases].
Topics: Amyloidosis; Glomerular Filtration Rate; Humans; Hypercalcemia; Hyperkalemia; Kidney Calculi; Metabo | 1980 |
[Incidence of metabolic disorders in patients with recurrent urinary calculi].
Topics: Adult; Aged; Calcium Oxalate; Creatinine; Diabetes Complications; Electrolytes; Female; Humans; Hydr | 1981 |
Asymptomatic hyperuricaemia and its early treatment.
Topics: Bicarbonates; Citrates; Citric Acid; Drug Combinations; Female; Humans; Male; Metabolic Diseases; So | 1980 |
Isolated defect in postsecretory reabsorption of uric acid.
Topics: Absorption; Adult; Benzbromarone; Female; Humans; Metabolic Diseases; Pyrazinamide; Uric Acid | 1980 |
[Secondary hyperuricemia (author's transl)].
Topics: Female; Gout; Humans; Male; Metabolic Diseases; Uric Acid | 1980 |
Behavioural and biological correlates of serum uric acid: a study of self-defence officials in Japan.
Topics: Aged; Alcohol Drinking; Body Weight; Creatinine; Diabetes Mellitus; Humans; Hyperlipidemias; Hyperte | 1994 |
[A metabolic study of urolithiasis. Specificity, sensitivity, efficacy and reproducibility].
Topics: Absorption; Adolescent; Adult; Aged; Calcium; Citrates; Citric Acid; Clinical Protocols; Creatinine; | 1995 |
[hypouricemia caused by xanthinuria].
Topics: Humans; Male; Metabolic Diseases; Middle Aged; Uric Acid; Xanthine; Xanthines | 1996 |
Epidemiological profile, mineral metabolic pattern and crystallographic analysis of urolithiasis in Kuwait.
Topics: Adolescent; Adult; Age Distribution; Aged; Calcium Oxalate; Chi-Square Distribution; Child; Family H | 1997 |
Risk factors for the incidence of hyperuricaemia: a 6-year longitudinal study of middle-aged Japanese men.
Topics: Age Factors; Alcohol Drinking; Cohort Studies; Comorbidity; Confidence Intervals; Humans; Incidence; | 1999 |
[Metabolic disorders in children with urolithiasis].
Topics: Calcium; Child; Child, Preschool; Female; Humans; Male; Metabolic Diseases; Uric Acid; Urinary Calcu | 2000 |
Metabolic abnormalities in patients with primary open-angle glaucoma.
Topics: Aged; Blood Glucose; Carbohydrate Metabolism; Diabetes Complications; Female; Glaucoma, Open-Angle; | 2001 |
Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors.
Topics: Allopurinol; Animals; Area Under Curve; Gout; Gout Suppressants; Male; Metabolic Diseases; Models, A | 2001 |
Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis.
Topics: Acidosis, Renal Tubular; Calcium; Calcium Phosphates; Cystine; Female; Humans; Kidney Calculi; Magne | 2001 |
[Vesical uric acid lithiasis in a child with renal hypouricemia].
Topics: Humans; Infant; Kidney Diseases; Male; Metabolic Diseases; Uric Acid; Urinary Bladder Calculi | 2001 |
Uric acid and the kidney.
Topics: Acute Kidney Injury; Ammonia; Animals; Glomerular Filtration Rate; Glutamine; Gout; Humans; Hydrogen | 1976 |
[Internal ear deafness and metabolic disorders].
Topics: Adult; Aged; Deafness; Diabetes Complications; Female; Humans; Hyperglycemia; Labyrinth Diseases; Ma | 1976 |
Diagnosis of hyperuricemia.
Topics: Humans; Metabolic Diseases; Uric Acid | 1979 |
Epidemiology of hyperuricemia in an ambulatory elderly population.
Topics: Age Factors; Aged; Female; Florida; Humans; Male; Metabolic Diseases; Multiphasic Screening; Referen | 1979 |
[Outpatient care in uric acid disorders].
Topics: Adult; Aged; Alcohol Drinking; Allopurinol; Ambulatory Care; Female; Humans; Male; Metabolic Disease | 1979 |
Gout and hyperuricaemia in Blacks.
Topics: Black or African American; Black People; Democratic Republic of the Congo; Female; Gout; Humans; Mal | 1977 |
[The significance of hyperuricacidemia in a new light].
Topics: Metabolic Diseases; Uric Acid | 1978 |
[Retinal thromboses with metabolic disturbances (author's transl)].
Topics: Adult; Age Factors; Aged; Female; Glucose; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Lip | 1978 |
[Functional limitations of the surgical operation in patients with ileostomy and colostomy].
Topics: Avitaminosis; Colostomy; Humans; Ileostomy; Metabolic Diseases; Nutrition Disorders; Postoperative C | 1978 |
[Definition and treatment requirements of uricemia].
Topics: Adult; Aged; Chronic Disease; Diabetes Mellitus; Female; Gout; Humans; Hypertension, Renal; Liver Di | 1977 |
Rheumatic disorders in the South African Negro. Part IV. Gout and hyperuricaemia.
Topics: Adolescent; Adult; Age Factors; Aged; Black People; Ethnicity; Female; Gout; Humans; Male; Metabolic | 1977 |
Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder.
Topics: Allopurinol; Calcium; Cystoscopy; Female; Hospitalization; Humans; Kidney Calculi; Male; Metabolic D | 1977 |
[De novo purine biosynthesis. In vitro measurement in hyperuricemia (author's transl)].
Topics: Adult; Allopurinol; Azaserine; Carbon Radioisotopes; Female; Formates; Gout; Humans; In Vitro Techni | 1977 |
[Hyperuricaemia and stenotic coronary atherosclerosis. A description of 214 recent cases of myocardial infarction (author's transl)].
Topics: Adult; Aged; Carbohydrate Metabolism; Coronary Disease; Female; Humans; Hyperlipidemias; Male; Metab | 1976 |
[Hyperuricemia and psoriasis].
Topics: Carbon Radioisotopes; Female; Glycine; Gout; Humans; Male; Metabolic Diseases; Psoriasis; Uric Acid | 1976 |
A clinical study of hyperuricaemic men.
Topics: Adult; Aortic Diseases; Blood Pressure; Coronary Disease; Humans; Male; Metabolic Diseases; Middle A | 1975 |
Antihypertensive drug therapy in USAF flying personnel.
Topics: Adult; Aerospace Medicine; Antihypertensive Agents; Electrocardiography; Gastrointestinal Hemorrhage | 1975 |
Acute uric acid nephropathy in thalassaemia.
Topics: Adult; Humans; Kidney Diseases; Kidney Pelvis; Male; Metabolic Diseases; Thalassemia; Uric Acid | 1975 |
Pediatric nephrolithiasis.
Topics: Acidosis, Renal Tubular; Adolescent; Adrenocortical Hyperfunction; Age Factors; Calcium; Child; Chil | 1975 |
Uric acid kinetic studies in the immediate post-myocardial-infarction period.
Topics: Body Weight; Carbon Radioisotopes; Creatinine; Humans; Kinetics; Lactates; Male; Metabolic Clearance | 1975 |
[Total colectomy. Its physiopathological sequelae].
Topics: Colectomy; Colonic Diseases; Follow-Up Studies; Humans; Ileostomy; Metabolic Diseases; Postoperative | 1975 |
[Recurrent Urolithiasis during Childhood (author's transl)].
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cystine; Czechoslovakia; Female; Focal Infection; | 1975 |
[Urolithiasis during childhood (author's transl)].
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cystine; Female; Focal Infection; Humans; Infant; | 1975 |
[Letter: Acute hyperuricemic kidney failure. Treatment by uricozyme].
Topics: Acute Kidney Injury; Adolescent; Humans; Metabolic Diseases; Urate Oxidase; Uric Acid | 1975 |
[Diffuse articular chondrocalcinosis and Paget's disease].
Topics: Adult; Aged; Alkaline Phosphatase; Chondrocalcinosis; Diabetes Complications; Female; Humans; Hydrox | 1975 |
[Correlation between purine metabolism disorder and hypertension].
Topics: Female; Fructose; Humans; Hypertension; Male; Metabolic Diseases; Middle Aged; Purines; Uric Acid | 1975 |
[Hypouricemia].
Topics: Humans; Kidney Diseases; Metabolic Diseases; Uric Acid; Uricosuric Agents | 1975 |
[Uricosuric agents: Should they be used in asymptomatic hyperuricemia?].
Topics: Allopurinol; Humans; Metabolic Diseases; Probenecid; Sulfinpyrazone; Uric Acid | 1976 |
Gout, uric acid and renal disease.
Topics: Arthritis; Gout; Humans; Kidney Diseases; Kidney Failure, Chronic; Metabolic Diseases; Uric Acid | 1976 |
Identification of the causes of persistent hyperuricaemia.
Topics: Humans; Kidney Diseases; Metabolic Diseases; Purines; Time Factors; Uric Acid | 1991 |
Uric acid metabolism in children.
Topics: Animals; Biological Transport; Child; Humans; Infant, Newborn; Kidney; Kidney Diseases; Metabolic Di | 1990 |
[Detection of metabolic disorders as a cause of urolithiasis in clinical practice].
Topics: Female; Male; Metabolic Diseases; Uric Acid; Urinary Calculi | 1989 |
Metabolic emergencies in pediatric oncology: the acute tumor lysis syndrome.
Topics: Child; Emergencies; Humans; Hyperkalemia; Hypocalcemia; Metabolic Diseases; Neoplasms; Phosphates; U | 1987 |
[Evaluation of hyperuricemia caused by fructose in a status of altered uric acid metabolism].
Topics: Adult; Aged; Arthritis, Gouty; Diagnosis, Differential; Female; Fructose; Gout; Humans; Male; Metabo | 1987 |
Adenosine triphosphate degradation in specific disease.
Topics: Adenine; Adenosine Triphosphate; Biotransformation; Carnitine O-Palmitoyltransferase; Ethanol; Fruct | 1985 |
Reversed-phase liquid-chromatographic determination of purine compounds in serum applied to studies of hypouricemia.
Topics: Adult; Aged; Allopurinol; Chromatography, High Pressure Liquid; Colorimetry; Female; Humans; Hypoxan | 1986 |
Allopurinol treatment of uric-acid disorders in calcium-stone formers.
Topics: Adult; Allopurinol; Calcium; Female; Follow-Up Studies; Humans; Kidney Calculi; Male; Metabolic Dise | 1973 |
Problems faced by hypertensive patients.
Topics: Adrenergic beta-Antagonists; Allopurinol; Blood Pressure; Contraceptives, Oral; Diuretics; Family Pr | 1973 |
[Incidence of primary hyperuricemia in ambulant patients (author's transl)].
Topics: Adult; Age Factors; Aged; Ambulatory Care; Blood Protein Disorders; Diabetes Mellitus; Female; Germa | 1974 |
[Side effects and complication possibilities following high-dosage furosemide treatment].
Topics: Adult; Aged; Alkalosis; Blood Coagulation Disorders; Blood Glucose; Dehydration; Drug Eruptions; Ear | 1972 |
Clinical experience with diazoxide.
Topics: Adenoma, Islet Cell; Adrenal Glands; Adult; Aged; Benzothiadiazines; Blood Glucose; Diabetes Mellitu | 1968 |
[Investigations concerning the incidence of disorders of lipid and carbohydrate metabolism in primary gout and symptomless hyperuricaemia (author's transl)].
Topics: Carbohydrate Metabolism; Cholesterol; Coronary Disease; Diabetes Complications; Female; Gout; Humans | 1974 |
Letter: Drugs used in hyperuricaemia.
Topics: Allopurinol; Anti-Inflammatory Agents; Gout; Humans; Metabolic Diseases; Uric Acid | 1974 |
Letter: A clinical impression of benzbromarone (Minuric).
Topics: Adult; Allopurinol; Benzoates; Benzofurans; Bromine; Gout; Gout Suppressants; Humans; Male; Metaboli | 1974 |
Proceedings: Hyper uricaemia in Sudanese.
Topics: Adult; Female; Humans; Male; Metabolic Diseases; Sudan; Uric Acid | 1974 |
Understanding hyperuricemia: nursing implications.
Topics: Allopurinol; Diabetes Mellitus; Diet Therapy; Gout; Humans; Kidney Diseases; Metabolic Diseases; Uri | 1972 |
Serum uric acid in normal and hypertensive Australian subjects.
Topics: Adolescent; Adult; Age Factors; Australia; Child; Colorimetry; Debrisoquin; Female; Guanethidine; Hu | 1972 |
Coronary heart disease in young men: a study of seventy patients with a critical review of etiological factors.
Topics: Adult; Australia; Body Height; Body Weight; Cholesterol, Dietary; Coronary Disease; Diabetes Complic | 1973 |
Endocrine and metabolic aspects of urology. Aetiology of stone formation in 145 renal stone patients.
Topics: Acidosis, Renal Tubular; Adolescent; Adult; Aged; Ammonia; Calcium; Calcium Metabolism Disorders; Ch | 1973 |
Serum uric acid levels in New Zealanders.
Topics: Adult; Age Factors; Aged; Female; Humans; Male; Metabolic Diseases; Middle Aged; New Zealand; Sex Fa | 1973 |
Proceedings: Treatment of acute leukaemia in adults.
Topics: Acute Disease; Adult; Allopurinol; Anti-Bacterial Agents; Bacterial Infections; Child; Cytarabine; D | 1974 |
Urinary stones: a prospective study of 350 patients.
Topics: Adult; Aged; Calcium; Cystinuria; Female; Humans; Hypercalcemia; Hyperglycemia; Male; Metabolic Dise | 1974 |
Some metabolic aspects of diseases of the locomotor system.
Topics: Body Weight; Calcinosis; Calcium Phosphates; Cartilage; Chondrocalcinosis; Female; Gout; Humans; Mal | 1973 |
Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase.
Topics: Allantoin; Aspergillus flavus; Gout; Humans; Injections, Intramuscular; Injections, Intravenous; Met | 1972 |
Necrobiotic nodules in association with hyperuricaemia and chondrocalcinosis.
Topics: Chondrocalcinosis; Humans; Male; Metabolic Diseases; Middle Aged; Radiography; Rheumatic Nodule; Uri | 1972 |
Rheumatology.
Topics: Acute Disease; Aged; Analgesics; Arthritis, Rheumatoid; Chronic Disease; Diazepam; Female; Gout; Hum | 1972 |
[Lipid disorders in gout and in hyperuricemia with myalgia].
Topics: Adult; Aged; Cholesterol; Female; Gout; Humans; Hypercholesterolemia; Hyperlipidemias; Lipids; Lipop | 1972 |
[Idiopathic femur head necrosis with hyperuricemia and dyslipemia in the adult].
Topics: Adolescent; Adrenocortical Hyperfunction; Adult; Aged; Allopurinol; Child; Diet Therapy; Female; Fem | 1972 |
Urate deposition disease. How is it regulated and how can it be modified?
Topics: Animals; Blood Proteins; Disease Models, Animal; Gout; Humans; Hydrogen-Ion Concentration; Kidney; K | 1973 |
[Lipid disorders in gout and hyperuricemias].
Topics: Cholesterol; Female; Gout; Humans; Hyperlipidemias; Lipids; Male; Metabolic Diseases; Phospholipids; | 1973 |
[Hypercalcemia and hyperuricemia in a patient with IgG myeloma treated with thyrocalcitonin].
Topics: Calcitonin; Evaluation Studies as Topic; Humans; Hypercalcemia; Immunoglobulin G; Male; Metabolic Di | 1973 |
Pregnancy bacteriuria: the significance of site of infection.
Topics: Anemia; Antibodies, Bacterial; Bacteriuria; Female; Fetal Death; Humans; Hypertension; Kidney Diseas | 1973 |
Hypouricemia in Hodgkin's disease. Report of an additional case.
Topics: Alcoholism; Hodgkin Disease; Humans; Male; Metabolic Diseases; Middle Aged; Uric Acid | 1973 |
[Dyspurinia and atherosclerosis].
Topics: Adult; Aged; Arteriosclerosis; Arteritis; Coronary Disease; Female; Gout; Humans; Intracranial Arter | 1973 |
[The aetiology of myocardial infarction in young people (author's transl)].
Topics: Adult; Age Factors; Contraceptives, Oral; Female; Humans; Infections; Male; Metabolic Diseases; Myoc | 1973 |
[What sould be done for a high concentration of blood urea?].
Topics: Acute Kidney Injury; Anemia; Bone Diseases; Calcium; Cardiovascular Diseases; Creatinine; Gastrointe | 1974 |
Editorial: Drugs used in hyperuricaemia.
Topics: Allopurinol; Gout; Humans; Metabolic Diseases; Uric Acid; Uricosuric Agents | 1974 |
The Jewish Hospital of St. Louis. Therapeutic grand rounds number 7. An approach to disorders of uric acid metabolism.
Topics: Allopurinol; Alloxan; Feedback; Gout; Guanine; Humans; Hypoxanthines; Kidney; Male; Metabolic Diseas | 1974 |
[Mechanism of serum uric acid rises under constant fructose infusion in man].
Topics: Adult; Extracellular Space; Fructose; Humans; Lactates; Metabolic Diseases; Parenteral Nutrition; Ur | 1971 |
The treatment of gout.
Topics: Acute Disease; Allopurinol; Colchicine; Diagnosis, Differential; Female; Gout; Humans; Indomethacin; | 1972 |
[Neurological complications in uricopathy].
Topics: Adult; Athetosis; Cardiovascular Diseases; Chorea; Compulsive Behavior; Female; Humans; Intellectual | 1972 |
Pediatric urolithiasis.
Topics: Acidosis, Renal Tubular; Calcium; Child; Cystinuria; Female; Hematuria; Humans; Male; Metabolic Dise | 1972 |
Should asymptomatic hyperuricaemia be treated?
Topics: Allopurinol; Gout; Humans; Kidney Calculi; Metabolic Diseases; Multiphasic Screening; Uric Acid; Uri | 1972 |
Hyperuricemia in health and disease.
Topics: Arteriosclerosis; Arthritis; Blood Group Antigens; Carbohydrate Metabolism; Diabetes Complications; | 1972 |
[Latent hyperuricemia].
Topics: Humans; Metabolic Diseases; Nucleic Acids; Uric Acid | 1971 |
[Renal functional disorders in patients with uric acid diathesis and their dynamics under treatment in Essentuki].
Topics: Adult; Female; Health Resorts; Humans; Kidney Diseases; Male; Metabolic Diseases; Middle Aged; Oxala | 1971 |
[Studies on uric acid metabolism in man. 2. Studies on uric acid metabolism in patients with hyperuricemia].
Topics: Adolescent; Adult; Aged; Female; Gout; Humans; Male; Metabolic Diseases; Middle Aged; Nephritis; Uri | 1971 |
[Urate diathesis and its treatment].
Topics: Diet Therapy; Metabolic Diseases; Nursing; Uric Acid | 1970 |
Hyperuricemia in cerebral infarction.
Topics: Adult; Aged; Blood; Female; Humans; Intracranial Arteriosclerosis; Intracranial Embolism and Thrombo | 1965 |
Hyperuricaemia and renal failure preceding the onset of acute lymphoblastic leukaemia.
Topics: Acute Disease; Acute Kidney Injury; Child; Humans; Leukemia, Lymphoid; Male; Metabolic Diseases; Uri | 1971 |
Prolonged nephrogram due to hyperuricaemia.
Topics: Female; Humans; Kidney; Kidney Diseases; Leukemia, Myeloid, Acute; Metabolic Diseases; Spleen; Uric | 1971 |
Dysmetabolic and neurological complications in leukemia patients treated with L-asparaginase.
Topics: Asparaginase; Central Nervous System Diseases; Child; Clinical Enzyme Tests; Drug Hypersensitivity; | 1970 |
What to do about an elevated uric acid level.
Topics: Gout; Metabolic Diseases; Uric Acid | 1969 |
Plasma uric acid levels in children.
Topics: Abdomen; Adolescent; Child; Child, Preschool; Female; Growth; Humans; Infant; Infant, Newborn; Male; | 1969 |
[Renal potassium loss. Case report of denied abuse of diuretics].
Topics: Adult; Alkalosis; Chlorine; Female; Furosemide; Humans; Metabolic Diseases; Natriuresis; Potassium; | 1969 |
[Biochemical studies in a typical case of xanthinuria].
Topics: Aged; Chromatography, Thin Layer; Clinical Enzyme Tests; Female; Humans; Hypoxanthines; Metabolic Di | 1970 |
[Symptomless hyperuricemia].
Topics: Gout; Humans; Metabolic Diseases; Uric Acid | 1970 |
Medical therapy of renal calculi.
Topics: Allopurinol; Calcium; Creatinine; Cystinuria; Diuresis; Humans; Kidney; Kidney Calculi; Magnesium; M | 1970 |
Renal tubular necrosis after gastroenteritis in infants.
Topics: Acute Kidney Injury; Animals; Gastroenteritis; Humans; Infant; Metabolic Diseases; Uric Acid | 1971 |
An unusual form of renal disease associated with gout and hypertension.
Topics: Adolescent; Adult; Aged; Biopsy; Cerebrovascular Disorders; Chromosome Aberrations; Chromosome Disor | 1971 |
Hyperuricaemia and gout.
Topics: Acute Disease; Adult; Arthritis; Chronic Disease; Diagnosis, Differential; Female; Gout; Humans; Mal | 1971 |
Effects of azathiprine in a disorder of uric acid metabolism and cerebral function.
Topics: Adult; Azathioprine; Blood Platelets; Brain Diseases; Child; Gout; Hematocrit; Hemoglobinometry; Hum | 1968 |
Hyperuricemia in neoplastic disease in children: prevention with allopurinol, a xanthine oxidase inhibitor.
Topics: Adolescent; Allopurinol; Blood Urea Nitrogen; Child; Child, Preschool; Female; Humans; Leukocyte Cou | 1968 |
Sulphobromophthalein retention in gout and asymptomatic hyperuricaemia.
Topics: Adolescent; Adult; Age Factors; Aged; Alcoholic Beverages; Female; Gout; Humans; Liver; Liver Diseas | 1968 |
Lesch-Nyhan syndrome: autopsy findings and in vitro study of incorporation of 14C-8-inosine into uric acid, guanosine-monophosphate and adenosine-monophosphate in the liver.
Topics: Adrenal Glands; Brain; Carbon Isotopes; Central Nervous System Diseases; Cerebellum; Humans; In Vitr | 1968 |
Cutaneous manifestation in combined lipids and urate metabolic disorders.
Topics: Diet Therapy; Female; Follow-Up Studies; Granuloma; Humans; Hypercholesterolemia; Hyperlipidemias; M | 1969 |
[Notes on etiopathogenesis and current trends of medical treatment of renal lithiasis].
Topics: Amino Acids; Calcium Metabolism Disorders; Carbohydrate Metabolism; Diet Therapy; Drug Therapy; Huma | 1969 |
Amino acid excretion in primary hyperuricaemia.
Topics: Amino Acids; Arginine; Biological Transport, Active; Glomerular Filtration Rate; Glycine; Kidney; Ki | 1969 |
[Therapy of asymptomic hyperuricemia].
Topics: Humans; Metabolic Diseases; Uric Acid; Urologic Diseases | 1969 |
Causes of hyperuricaemia.
Topics: Diet; Female; Gout; Hematopoiesis; Humans; Intellectual Disability; Male; Metabolic Diseases; Purine | 1969 |
Hyperuricaemia: some biochemical aspects.
Topics: Adenine; Carbon Isotopes; Glycine; Humans; In Vitro Techniques; Intellectual Disability; Metabolic D | 1969 |
Management of gout.
Topics: Acute Disease; Allopurinol; Chronic Disease; Colchicine; Gout; Humans; Indomethacin; Metabolic Disea | 1969 |
Uric acid and plasma lipids in cerebrovascular disease. I. Prevalence of hyperuricaemia.
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Cerebrovascular Disorders; Cyanides; Female; Humans; Mal | 1969 |
[II. Disorders of uric acid metabolism and their importance].
Topics: Humans; Metabolic Diseases; Uric Acid | 1965 |